The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Interim results of phase II study shows survival benefit of THIO in NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MAIA Biotechnology Inc. announced results showing a favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced non-small cell lung cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated NSCLC treated with intravenous Rybrevant

Johnson & Johnson announced results from the open-label phase II SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions with intravenous Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. 
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account